Anti-inflammatory, Anti-oxidant, and Vasodilating Effect of Evening Primrose Oil in Type 2 Diabetic Patients

Mustafa SaffaHussain1, Manal Khalid Abdulridha2*, Mahmood Shaker Khudhair3

1Ali-Kadhimiyah hospital, Ministry of Health, Iraq.
2Department of Clinical Pharmacy, College of Pharmacy, Al-Mustansiriyah University, Iraq.
3Consultant Endocrinologist, Department of Internal Medicine, College of Medicine, Al-Nahrain University, Iraq.

*Corresponding author’s E-mail: mkar_3564@yahoo.com

Accepted on: 10-06-2016; Finalized on: 31-07-2016.

ABSTRACT

Type 2 diabetes mellitus (T2DM) is considered as the most common disease in modern societies. Natural products or compounds reported as useful remedies for controlling or preventing T2DM are categorized into five major groups: anti-inflammation products, AMPK activators, insulin secretion stimulators, alpha-glucosidase/disaccharidase or amylase inhibitors and products acting with an unknown mechanism. Evening primrose oil is a substantial source of omega-6 essential fatty acids, mostly gamma-linolenic acid (GLA). Linolenic acid (LA) forms GLA by Δ-6-desaturase enzyme. The activity of Δ-6-desaturase enzyme is compromised in patients with type 2 diabetes. Accordingly, this study aims to evaluate the effect of evening primrose oil in reducing the complications of type 2 diabetes mellitus. Twenty six Iraqi patients newly diagnosed with type 2 diabetes who are either overweight or obese. Thirteen patients received metformin 500 mg tablets twice daily alone, and 13 patients received metformin 500 mg plus evening primrose oil 2 gm capsule twice daily for a three-month therapy. Serum hs-CRP, Tumor necrosis factor α, and malondialdehyde (MDA) were measured. There was statistically significant elevation in baseline levels of serum MDA, hs-CRP, and TNF-α, and in both systolic and diastolic blood pressure in both patient groups compared with control subjects, (P< 0.001). High reduction after three months of treatment was found in these parameters compared with a pre-treatment level, significantly with serum MDA, TNF-α, and in both systolic and diastolic BP in patients group receiving evening primrose oil (P< 0.001). It can be concluded that early intervention with natural oil rich in gamma linolenic acid, which possess anti-angiogenic, anti-inflammatory, and anti-oxidant activities, with traditional hypoglycemic drugs can improve therapeutic benefits and represent a promising strategy to restrain the progression of diabetes complications.

Keywords: Evening primrose-Oenotherabiennis, Type 2 diabetes mellitus, anti-inflammatory, anti-oxidant activities.

INTRODUCTION

Type 2 diabetes mellitus (T2DM) is considered the most common disease in modern societies3. The prevalence of type 2 diabetes mellitus is increasing worldwide, parallel to the current obesity epidemic3. Nearly 23% of patients with morbid obesity have type 2 diabetes mellitus and the spread of screening-detected diabetes is 8%2. The universal epidemic of T2DM is tied to rising rates of overweight and obesity in adults as well as in youth5. Many of oral antidiabetic agents have been developed through the last 40 years4. Safety considerations must always be carefully considered with selection of the hypoglycemic agents5.

Development and use of natural products as therapeutic agents, especially those prepared from plants have been intensified in recent years. Some naturally occurring anti-hyperglycemic phytochemicals have been suggested as potential drugs for the treatment of T2DM6. Natural products or compounds reported as useful remedies for controlling or preventing T2DM are categorized into five major groups: anti-inflammation products, adenosine monophosphate-activated protein kinase (AMPK) activators, insulin secretion stimulators, alpha-glucosidase/disaccharidase or amylase inhibitors, and products acting with an unknown mechanism6. Evening primrose-Oenotherabiennis is a prevalent plant which exists in the temperate regions of North America, Europe and South America. Evening primrose is basically a wild flower that belongs to the genus of Oenothera7. Historically, evening primrose (Oenothera spp.) has been grown both as a charming wild flower and as an herbal supplement. Increasingly, evening primrose oil (EPO) has been recognized by the medical society as a valid health care product8. Evening primrose was a fundamental food for many Native American clans and a famine food for Chinese farmers.

European settlers and Native Americans used the entire plant to improve ailments such as bruising, stomachaches, and shortness of breath8. Evening primrose oil is extracted from the seeds of Oenotherabiennis. Evening primrose oil is a substantial source of omega-6 essential fatty acids, mostly gamma-linolenic acid (GLA) and linoleic acid (LA), both major components of myelin and the neuronal cell membrane19.

Researchers have found that the high concentrations of GLA found in evening primrose oil can be used to treat several pathological conditions in humans caused by GLA deficiencies. Supplementation of the diet with the GLA extracted from the oil of plants such as evening primrose is thought to minimize the severity of many diseases8.
Gamma-linolenic acid has anti-inflammatory, antithrombotic, and lipid reducing effect. It also enhances smooth muscle relaxation and vasodilatation. In addition, essential fatty acids including GLA are substantial constituents of membrane phospholipids, including the mitochondrial membrane, where they promote the integrity and fluidity of the membrane. Linolenic acid (LA) forms GLA by Δ-6-desaturase enzyme. Gamma-linolenic acid forms di-homo-gamma-linolenic acid (DGLA), which can be turned into prostaglandin E1 (PGE1) or to arachidonic acid (AA) byproducts (eg, series 2 prostaglandins [PGE2], leukotrienes, and thromboxane). Prostaglandin E1 is preferentially created because the conversion from DGLA to arachidonic acid is slower. The activity of Δ-6-desaturase enzyme, which is compromised in patients with type 2 diabetes. Action of this enzyme further decreases with age and in people suffering from diverse diseases, including arthritis, diabetes, hypertension, eczema, psoriasis, and so on. Lifestyle factors like stress, smoking, overconsumption of alcohol, saturated and trans-fatty acids and nutritional deficiencies of Vitamin B6, zine, and magnesium suppress this desaturase. As a result of restrictions in vivo production of GLA, supplementation with preformed GLA is becoming substantial. This has led to attention in development and commercialization of the sources of GLA.

Accordingly, this study aims to evaluate the effect of evening primrose oil in reducing the complications of type 2 diabetes mellitus via its anti-inflammatory and antioxidant consequently reduces the microvascular complications of T2 DM, and also to assess its smooth muscle relaxation and vasodilatation effect by reducing the BP as a risk for other macrovascular complications.

**PATIENTS AND METHODS**

**Study Design**

This is a prospective randomized controlled interventional open label study to evaluate the efficacy of primrose oil in T2 diabetic patients.

**Patients**

Twenty Six Iraqi patients newly diagnosed with type 2 diabetes mellitus with age ranges between (35-60) years were enrolled in this study. Both genders were eligible for the study.

Sixteen patients were female and 10 patients were male. Most of patients were either overweight having a BMI ranging from 25-29.9 kg/m² or obese with a BMI (≥30) kg/m².

Fourteen apparently healthy control subjects were included in the study. Patients will be treated according to routine clinical practice at the discretion of the treating physician. The eligible patients and subjects were allocated into three main groups:

**Group 1**

Includes 13 patients diagnosed with type 2 diabetes were assigned to receive metformin 500 mg tablets twice daily alone (as a conventional therapy) for a three-month therapy (as an active comparator).

**Group 2**

Includes 13 patients diagnosed with type 2 diabetes were assigned to receive metformin 500 mg plus evening primrose oil 2 gm capsule twice daily for a three-month therapy.

**Group 3**

Includes 14 apparently healthy control subjects.

Ethics approval was obtained from the Institutional Scientific Committee.

**Materials**

**Drugs, Chemical and their Suppliers**

<table>
<thead>
<tr>
<th>Chemicals and Drugs</th>
<th>Suppliers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kit for serum MDA</td>
<td>SHANGHAI YEHUA Biological Technology Co., Ltd.</td>
</tr>
<tr>
<td>Kit for serum TNF alpha</td>
<td>SHANGHAI YEHUA Biological Technology Co., Ltd</td>
</tr>
<tr>
<td>Kit for serum human hs-CRP</td>
<td>Cusabio</td>
</tr>
<tr>
<td>Glucophage (metformin) 500 mg tablet</td>
<td>Merck</td>
</tr>
<tr>
<td>Evening primrose oil 1000 mg softgel capsule</td>
<td>Vitane</td>
</tr>
</tbody>
</table>

**Methods**

All patients were fasting (12-14) hr calories free diet. Ten ml of venous blood were drawn using a plastic disposable syringe of 10ml capacity to measure the inflammatory and oxidative stress marker.

Serum hs-CRP, Tumor necrosis factor-α(TNF-α), and the concentration of human malondialdehyde (MDA) were measured using the enzyme-linked immune sorbent assay (ELISA). A blood pressure reading was recorded using manual sphygmomanometer device.

**Statistical Analysis**

Data were translated into a computerized database structure, and the statistical analyses were carried out using the computer program SPSS version 20 (Statistical Package for Social Sciences-version 20). The results were expressed as mean±SD. Data were statistically evaluated using paired t-test to compare between pre and post treatment results among the study groups. Values with P<0.05 were considered significantly different.
RESULTS AND DISCUSSION

Patients Demographic Characteristics

The demographic data of the 40 subjects included in this study were presented in Table 1 where 22 patients were female (55%) and 18 patients were male gender (45%) with no statistical difference found between study groups in respect to both genders. The mean age of the study groups was as follows: control group (42.5±5) years, Group 1 (48.6±7.1) years, and Group 2 patients was (49.3±6.6) years. The mean BMI value of control subjects was (26.7±0.8) kg/m², while in the patient groups was (29.2±1.9) kg/m² in Group 1, and (29.2±1.6) kg/m² with Group 2. Statistical difference was found between patient groups and control subjects (P<0.001).

Table 1: Patients Demographic Characteristic

<table>
<thead>
<tr>
<th>Variables</th>
<th>Study Groups</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Control</td>
</tr>
<tr>
<td>n</td>
<td>%</td>
</tr>
<tr>
<td>Gender</td>
<td>14</td>
</tr>
<tr>
<td>Female</td>
<td>6</td>
</tr>
<tr>
<td>Total</td>
<td>100</td>
</tr>
</tbody>
</table>

Changes in Oxidation and Inflammation Markers in Type 2 Diabetic Patients Treated for Three Months

In the present study, there was significant elevation in baseline level of both serum MDA and TNF-α in patient groups 1 and 2 compared with control subjects, with statistically high difference found between patient groups and control subjects (P< 0.001). Also highly significant reduction in serum MDA and TNF-α level after three months of treatment was found in Group 2 patients only compared with pre-treatment level (P< 0.001), but no significant reduction was found in Group 1 patients compared with a pre-treatment level (P>0.05) (Table 2). The serum hs-CRP in both patient Groups 1 and 2 was statistically high compared with control subjects (P< 0.001), and highly significant reduction in serum hs-CRP level after three months of treatment was found in both patients groups compared with a pre-treatment level (P< 0.001), with no significant difference between patient groups.

Table 2: Oxidation and Inflammation Markers in Type 2 Diabetic Patients Treated for Three Months

<table>
<thead>
<tr>
<th>Variables</th>
<th>Study Groups</th>
<th>Pre treatment</th>
<th>Post treatment</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>MDA nmol/ml</td>
<td>Control</td>
<td>5.73±1.52</td>
<td>.</td>
<td>0.128 NS</td>
</tr>
<tr>
<td></td>
<td>Group 1</td>
<td>10.53±0.72**</td>
<td>9.92±0.63</td>
<td>.</td>
</tr>
<tr>
<td></td>
<td>Group 2</td>
<td>10.51±0.8**NS</td>
<td>8.81±1.1b**</td>
<td>.</td>
</tr>
<tr>
<td></td>
<td>Group 1</td>
<td>4.66±0.73***</td>
<td>4.02±0.67</td>
<td>.</td>
</tr>
<tr>
<td>hs-CRP ng/l</td>
<td>Control</td>
<td>2.64±0.76</td>
<td>.</td>
<td>.</td>
</tr>
<tr>
<td></td>
<td>Group 2</td>
<td>4.63±0.63**NS</td>
<td>3.96±0.53NS</td>
<td>.</td>
</tr>
<tr>
<td></td>
<td>Group 1</td>
<td>120.37±21.95</td>
<td>.</td>
<td>.</td>
</tr>
<tr>
<td></td>
<td>Group 2</td>
<td>275.29±62.18***</td>
<td>245.59±55.75</td>
<td>.</td>
</tr>
<tr>
<td></td>
<td>Group 2</td>
<td>264.79±65.14**NS</td>
<td>200.59±67.13b*</td>
<td>.</td>
</tr>
</tbody>
</table>

Data presented as mean±SD and number (n) and percentage (%) were:

NS: Not significant (p>0.05), * Significant difference (p<0.05), ** Highly Significant difference (p<0.001)
Hyperglycemia may induce oxidative stress and the possible mechanisms for inducing such stress were well documented as mentioned earlier. Fortunately, in the present study, the addition of evening primrose oil to metformin in newly diagnosed T2DM patients produced significant reduction (p<0.05) in serum MDA concentration in comparison with patients treated with metformin alone, which means that evening primrose oil may have promising antioxidant effect in these patients. This result was compatible with that of DE La Cruz where the addition of evening primrose oil to the normolipemic and hyperlipemic rabbits decreased the level of serum MDA that mean reduce the lipid peroxide production and enhance the antioxidant activity of glutathione. 

Recently and experimentally, El-Sayed in his study, found restoration of joint activity and antioxidant status by daily treatment of evening primrose oil with aspirin or celecoxib produced a significant reduction in serum MDA levels compared to aspirin or celecoxib alone. Another recent study on the use as antioxidant of a mixture of \( \omega-3 \) lipids and evening primrose oil has evidenced an improvement in neuropathic pain through increased PGE1 synthesis.

Despite of the potent anti-inflammatory effect of metformin, the present study found that adding evening primrose oil to metformin produced significant reduction in TNF-\( \alpha \) concentration in patients treated with metformin alone, a promising anti-inflammatory effect of the GLA in this result is compatible with the previous study observed anti-inflammatory and anti-angiogenic activities which was confirmed by histopathological findings and revealed that EPO significantly reduced the synovial hyperplasia and inflammatory cells invasion in joint tissues, since gamma linolenic acid could suppress inflammatory cytokines level in human blood lymphocytes.

Manal found that addition of EPO to arthritic rats produced significant reduction in IL-4 and TNF-\( \alpha \) levels. The EPO is richin omega-6 essential fatty acids particularly GLA which gives anti-inflammatory properties. Previous studies have reported that the therapeutic anti-inflammatory effects of EPO may be due to the direct action of its component essential fatty acids on immune cells, as well as their indirect effect on the synthesis of eicosanoids such as prostaglandins, cytokines and cytokine mediators.

In a retrospective study, there was a strong and graded association of serum hs-CRP level with the incidence of diabetes independent of established risk factors. Similar significant elevation in the level of the serum hs-CRP was found in the present study T2DM patients compared to control subjects. The addition of evening primrose oil to metformin showed slight but not significant reduction in serum hs-CRP concentration in comparison with patients on metformin alone. Previous results also showed no significant effect of the addition of GLA (the essential ingredient in the EPO) on CRP formation. Belch also confirmed that the addition of EPO to the patients with rheumatoid arthritis did not produce significant effect on CRP level.

The patients were overweight, and the role of adipose tissues in metabolic dysfunctions has long been considered but their potential role in inflammatory processes is a new expanding concept because this tissue is an important metabolically active endocrine organ that secretes various hormones and cytokines, known as adipokines.

Adipokines targets several tissues and cell types, and one of its major actions is to control hepatic production of inflammatory proteins such as CRP, which is an important cardiovascular risk factor. Accordingly, all these findings can explain the non-significant differences between patient groups and a different percent of reduction in this parameter after three months.

**Blood Pressure Changes in Type 2 Diabetic Patients Treated for Three Months**

There were statistically significant elevations in baseline level of systolic and diastolic B.P in both patient groups 1 and 2 compared with control subjects (\( p<0.05 \)). Also significant reduction in B.P level after three months of treatment was found in Group 2 patients only compared with a pre-treatment level (\( p<0.01 \)), but no significant reduction was found in Group 1 patients compared with a pre-treatment level (\( p>0.05 \)) (Table 3).

<table>
<thead>
<tr>
<th>Variable</th>
<th>Study Groups</th>
<th>Pre treatment</th>
<th>Post treatment</th>
<th>( P ) value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Systolic mmHg</strong></td>
<td>Control</td>
<td>127.86±6.99</td>
<td>136.15±5.06</td>
<td>0.531&lt;sup&gt;NS&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>Group 1</td>
<td>134.62±6.6&lt;sup&gt;**&lt;/sup&gt;</td>
<td>128.46±5.55&lt;sup&gt;**&lt;/sup&gt;</td>
<td>&lt;0.01&lt;sup&gt;*&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>Group 2</td>
<td>134.62±6.6&lt;sup&gt;**NS&lt;/sup&gt;</td>
<td>128.46±5.55&lt;sup&gt;**NS&lt;/sup&gt;</td>
<td>&lt;0.01&lt;sup&gt;*&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>Diastolic mmHg</strong></td>
<td>Control</td>
<td>82.14±4.26</td>
<td>.</td>
<td>.</td>
</tr>
<tr>
<td></td>
<td>Group 1</td>
<td>85.38±5.19&lt;sup&gt;**&lt;/sup&gt;</td>
<td>86.92±4.8</td>
<td>0.422&lt;sup&gt;NS&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>Group 2</td>
<td>84.62±5.19&lt;sup&gt;**NS&lt;/sup&gt;</td>
<td>83.08±4.8&lt;sup&gt;**NS&lt;/sup&gt;</td>
<td>&lt;0.01&lt;sup&gt;*&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

Data presented as mean ± SD were: <sup>1</sup>Comparison with control group, <sup>2</sup>Comparison with Group 1

<sup>NS</sup>: Not significant (\( p>0.05 \)), <sup>*</sup> Significant difference (\( p<0.05 \)), <sup>**</sup> Highly Significant difference (\( p<0.001 \))
The increase in the systolic blood pressure and diastolic blood pressure is the major risk for macrovascular complications in T2DM. In the present study, the combination of evening primrose oil and metformin significantly reduced both systolic blood pressure and diastolic blood pressure compared to metformin alone (p<0.05).

This effect was due to the vasodilator effect of GLA founded in EPO, which, when converted in the body to prostaglandin E1, will produce anti-inflammatory, antiplatelet, and vasodilating properties. This result is also compatible with a previously mentioned study where supplementation with EPO in patients with impaired glucose tolerance showed significant lowering of both systolic and diastolic blood pressure. Another study done by Catherine confirmed a significant difference in systolic and/or diastolic blood pressure between users and non-users of this dietary supplements.

CONCLUSION

Up to our knowledge, we are aware of no randomized controlled trial that assessed the effect of EPO administration on metabolic and inflammatory makers in type 2 diabetic patients, particularly among Iraqi patients. The significant reduction in serum MDA and TNF-α levels after three months of combining evening primrose oil supplement to the conventional metformin therapy at the onset of diagnosis, no doubt, shows that GLA plays a pivotal role in disease process, and the dietary control of fatty acid intake would be expected to modify the disease progression.

It can be concluded that early intervention with natural oil rich in gamma linolenic acid, which possesses anti-angiogenic, anti-inflammatory, and anti-oxidant activities, with traditional hypoglycemic drugs can improve therapeutic benefits and represent a promising strategy to restrain the progression of diabetes complications.

REFERENCES

18. Ismail MF, El-Maraghy SA, Sadik NA. Study of the immune modulatory and anti-inflammatory effects of evening

**Source of Support:** Nil, **Conflict of Interest:** None.